4F 4PP oxalate

CAS No. 144734-36-1

4F 4PP oxalate( —— )

Catalog No. M23612 CAS No. 144734-36-1

4F 4PP oxalate is a 5-HT2A antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
10MG 48 In Stock
25MG 88 In Stock
50MG 144 In Stock
100MG 214 In Stock
200MG 305 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    4F 4PP oxalate
  • Note
    Research use only, not for human use.
  • Brief Description
    4F 4PP oxalate is a 5-HT2A antagonist.
  • Description
    4F 4PP oxalate is a 5-HT2A antagonist.
  • In Vitro
    ——
  • In Vivo
    4F 4PP (100 nM) reduces the lowest [D-ala2,N-me-phe4,gly.l5]-enkephalin (DAMGO) concentration and can produce a significant depression of evoked field potentials.
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    5-HT2A
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    144734-36-1
  • Formula Weight
    429.49
  • Molecular Formula
    C22H26FNO·C2H2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mM;Ethanol:20 mM
  • SMILES
    OC(C(O)=O)=O.FC1=CC=C(C(C2CCN(CC2)CCCCC3=CC=CC=C3)=O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Aira Z , Buesa I , Ca?O G , et al. Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors[J]. Pain, 2012, 153(7):1418-1425.
molnova catalog
related products
  • SB-258585

    SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM.

  • Urapidil hydrochlori...

    Urapidil hydrochloride is an α1-adrenoceptor antagonist and 5-HT1A receptor agonist.

  • Pergolide mesylate s...

    PERGOLIDE MESYLATE is a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemiabut withdrawn from some markets due to potential for heart valve diseases.